A recent study discussed in Applied Clinical Trials sheds light on the influence of assigned roles on patient-reported outcomes (PROs) in clinical trials. Here are the key insights: 💡 Role Assignment Dynamics: The study delves into how patients' assigned roles within clinical trials can significantly impact their reported outcomes. This highlights the importance of considering not just treatment efficacy but also the psychosocial factors associated with different trial roles. 💡Patient Perception: Patients' perceptions of their roles, whether as active participants or controls, can influence their engagement and subsequent reporting of outcomes. Understanding these dynamics is crucial for optimising trial design and interpretation of results. 💡Implications for Trial Design: The findings underscore the need for thoughtful consideration of role assignments in trial design. Tailoring roles to maximise patient engagement and minimise bias can enhance the reliability and validity of PROs, ultimately strengthening the integrity of clinical trial data. 💡Enhancing Patient-Centricity: By recognising the impact of role assignments on PROs, trial sponsors can prioritise patient-centric approaches that prioritise patient well-being and participation. This fosters a more inclusive and collaborative clinical trial environment. By addressing he nuanced relationship between assigned roles and patient-reported outcomes in clinical trials thoughtfully, researchers can enhance the quality and relevance of trial results, ultimately benefiting patients and advancing medical science. Read the full article here: https://bit.ly/3WTDT2o #ClinicalTrialRoles #PatientReportedOutcomes #TrialDesign #PatientCentricity
Goodland Pharma’s Post
More Relevant Posts
-
As the world of work undergoes a dramatic transformation, the recruitment landscape is always ripe for innovation! Enter new tech like HCLTech's SmartRecruit – a GenAI-powered solution that aims to redefine the way organisations attract, evaluate, and onboard top talent. Powered by Amazon Bedrock, the platform leverages the latest advancements in Generative AI to automate key recruitment tasks, eliminate bias, and deliver a personalised experience for candidates and hiring teams alike. Read about this promising new tech in an interview with its creators: https://bit.ly/3LouLMp #RecruitmentTransformation #GenAIInnovation #TalentAcquisition #HiringOptimisation #FutureOfWork
-
-
At Goodland Pharma, we understand that one-size-fits-all solutions simply don't work in the dynamic life sciences industry. That's why we offer tailored expertise, immersing ourselves in your unique culture and requirements to deliver exceptional results. Partner with us. Experience recruitment redefined. Let us help: https://bit.ly/4cFaiis #CustomisedRecruitment #LifeSciencesExpertise #IndustrySpecificSolutions #FlexibleServices #TailoredApproach
-
-
As clinical trials become increasingly competitive, with over 450,000 ongoing globally, traditional recruitment methods often fall short. Key strategies to combat this with emerging solutions include leveraging digital marketing and AI tools, partnering with patient advocacy groups, and simplifying eligibility criteria to optimise participant engagement and retention. By adopting innovative approaches that incorporate the patient voice, clinical trial sponsors and sites can overcome recruitment obstacles and achieve higher enrolment rates. Read the full article here: https://bit.ly/45KcxOu #ClinicalTrials #PatientRecruitment #DigitalMarketing #PatientEngagement #DrugDevelopment
-
-
With a footprint spanning 6 continents and over 10,000 connections, Goodland Pharma's extensive global network unlocks access to the world's top clinical talent. Together, we'll achieve your vision without boundaries. Partner with us today and take your life science projects to new heights. Get started here: https://bit.ly/3IX7TlK #GlobalRecruitment #TalentAcquisition #LifeSciencesCareer #InternationalHiring #WorldwideTalent
-
-
A recent review explored 2 different breakthrough therapies for Multiple Myeloma: CAR-T and BsAbs. ✳️ The landscape of multiple myeloma (MM) treatment has undergone a remarkable evolution, with novel agents revolutionising therapeutic strategies. Among these, B-cell maturation antigen (BCMA) has emerged as a promising target, leading to the development of innovative immune approaches. ✳️ Immunotherapies leveraging chimeric antigen receptor (CAR)-engineered T-cells and bispecific antibodies (BsAbs) have garnered significant attention in MM treatment, demonstrating superior potential over conventional regimens. Recent clinical trials underscore their efficacy, positioning them as pivotal players in MM management. ✳️ However, while CAR-T and BsAbs targeting BCMA offer breakthrough potential, their integration into clinical practice presents challenges. This review delves into associated limitations, emphasising the importance of patient selection and treatment customisation. Optimising efficacy and minimising toxicity through strategic combination or sequencing of therapies is paramount, particularly for patients with limited treatment options. Read the full review here: https://bit.ly/3wRO5ha #MultipleMyeloma #Immunotherapy #CAR-T #BsAbs
-
-
At Goodland Pharma, our expertise is not just broad; it's deeply specialised in the pivotal areas that drive the success of clinical trials worldwide. With a laser focus on Clinical Operations, Regulatory Affairs, and Quality Assurance, we're dedicated to providing unmatched support and talent solutions tailored to your precise needs. We're equipped to meet your recruitment needs with precision and efficiency, helping you achieve your goals with confidence. Get started here: https://lnkd.in/g_z8FmWD #GoodlandPharma #RecruitmentPartnership #ClinicalTrials #LifeScience
-
-
New study highlights benefits of CRT-D in non-ischemic cardiomyopathy patients! Cardiac resynchronisation therapy (CRT) has long been heralded as a breakthrough for heart failure patients with electrical desynchrony. A recent meta-analysis comparing CRT with implantable cardioverter-defibrillator (CRT-D) to CRT with pacemaker only (CRT-P) in non-ischemic cardiomyopathy (NICM) patients sheds light on its efficacy. The study, pooling data from 13 studies and over 61,000 patients, found that CRT-D significantly lowers the risk of all-cause mortality compared to CRT-P (pooled HR 0.74; 95% CI: 0.62-0.88). However, this benefit was not observed in patients older than 75 years. While CRT-D didn't show a significant reduction in cardiovascular mortality, its impact on overall survival underscores its importance in managing NICM. More details from the full article here: https://bit.ly/3yzELz4 #HeartFailure #CRTTherapy #Defibrillator #Cardiomyopathy
-
-
We believe in leveraging our expertise and resources to contribute meaningfully to the advancement of healthcare. At the end of the day, our success is measured by the positive impact we have on others. Trust us to be your ally in realising your goals and making a difference where it matters most. Check out our website for more: https://lnkd.in/g_z8FmWD #GoodlandPharma #LifeScience #ClinicalTrials #RecruitmentPartnership
-
-
We're not just here to fill positions and collect fees – we're here to build lasting partnerships rooted in genuine care and support. Our commitment to ethical recruitment practices extends beyond business transactions; it's a reflection of our core values and dedication to making a positive impact in the world. That's why you'll find us here, actively engaging and providing valuable insights to help improve medicine and enhance the lives of patients. Get in touch today: https://lnkd.in/g_z8FmWD #GoodlandPharma #LifeScience #ClinicalTrials #RecruitmentPartnership
-
